vs
Side-by-side financial comparison of ACNB CORP (ACNB) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $47.2M, roughly 1.4× ACNB CORP). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 22.9%, a 16.5% gap on every dollar of revenue. ACNB CORP produced more free cash flow last quarter ($52.6M vs $43.5M).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
ACNB vs SLNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $66.0M |
| Net Profit | $10.8M | $26.0M |
| Gross Margin | — | 98.3% |
| Operating Margin | 27.9% | 33.5% |
| Net Margin | 22.9% | 39.4% |
| Revenue YoY | 42.2% | — |
| Net Profit YoY | 63.8% | 134.0% |
| EPS (diluted) | $1.10 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | — | ||
| Q3 25 | $50.9M | $66.0M | ||
| Q2 25 | $50.3M | $32.7M | ||
| Q1 25 | $43.5M | — | ||
| Q4 24 | $33.2M | — | ||
| Q3 24 | $34.1M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $31.6M | — |
| Q4 25 | $10.8M | — | ||
| Q3 25 | $14.9M | $26.0M | ||
| Q2 25 | $11.6M | $-4.7M | ||
| Q1 25 | $-272.0K | — | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $11.3M | — | ||
| Q1 24 | $6.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 27.9% | — | ||
| Q3 25 | 37.2% | 33.5% | ||
| Q2 25 | 29.7% | -20.0% | ||
| Q1 25 | -1.3% | — | ||
| Q4 24 | 24.8% | — | ||
| Q3 24 | 27.6% | — | ||
| Q2 24 | 42.8% | — | ||
| Q1 24 | 26.9% | — |
| Q4 25 | 22.9% | — | ||
| Q3 25 | 29.2% | 39.4% | ||
| Q2 25 | 23.2% | -14.4% | ||
| Q1 25 | -0.6% | — | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 21.4% | — |
| Q4 25 | $1.10 | — | ||
| Q3 25 | $1.42 | $0.47 | ||
| Q2 25 | $1.11 | $-0.09 | ||
| Q1 25 | $-0.03 | — | ||
| Q4 24 | $0.77 | — | ||
| Q3 24 | $0.84 | — | ||
| Q2 24 | $1.32 | — | ||
| Q1 24 | $0.80 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $498.9M |
| Total DebtLower is stronger | $255.4M | — |
| Stockholders' EquityBook value | $420.0M | $494.8M |
| Total Assets | $3.2B | $599.9M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | — | ||
| Q3 25 | $102.1M | $498.9M | ||
| Q2 25 | $103.1M | $286.8M | ||
| Q1 25 | $123.6M | — | ||
| Q4 24 | $47.3M | — | ||
| Q3 24 | $58.1M | — | ||
| Q2 24 | $86.3M | — | ||
| Q1 24 | $53.1M | — |
| Q4 25 | $255.4M | — | ||
| Q3 25 | $255.4M | — | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | — | ||
| Q4 24 | $255.3M | — | ||
| Q3 24 | $255.3M | — | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | — |
| Q4 25 | $420.0M | — | ||
| Q3 25 | $408.6M | $494.8M | ||
| Q2 25 | $395.2M | $240.1M | ||
| Q1 25 | $386.9M | — | ||
| Q4 24 | $303.3M | — | ||
| Q3 24 | $306.8M | — | ||
| Q2 24 | $289.3M | — | ||
| Q1 24 | $279.9M | — |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.3B | $599.9M | ||
| Q2 25 | $3.3B | $332.3M | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.4B | — |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $43.5M |
| Free Cash FlowOCF − Capex | $52.6M | $43.5M |
| FCF MarginFCF / Revenue | 111.4% | 65.8% |
| Capex IntensityCapex / Revenue | 2.3% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.96× | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | — | ||
| Q3 25 | $23.2M | $43.5M | ||
| Q2 25 | $17.8M | $-12.6M | ||
| Q1 25 | $-71.0K | — | ||
| Q4 24 | $39.8M | — | ||
| Q3 24 | $13.6M | — | ||
| Q2 24 | $9.7M | — | ||
| Q1 24 | $10.8M | — |
| Q4 25 | $52.6M | — | ||
| Q3 25 | $22.8M | $43.5M | ||
| Q2 25 | $17.6M | $-12.6M | ||
| Q1 25 | $-730.0K | — | ||
| Q4 24 | $38.8M | — | ||
| Q3 24 | $13.3M | — | ||
| Q2 24 | $9.4M | — | ||
| Q1 24 | $10.7M | — |
| Q4 25 | 111.4% | — | ||
| Q3 25 | 44.7% | 65.8% | ||
| Q2 25 | 35.0% | -38.6% | ||
| Q1 25 | -1.7% | — | ||
| Q4 24 | 117.0% | — | ||
| Q3 24 | 39.1% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 33.9% | — |
| Q4 25 | 2.3% | — | ||
| Q3 25 | 0.8% | 0.0% | ||
| Q2 25 | 0.4% | 0.0% | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | 1.67× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
